Abstract #2427

Ultra-high field Dynamic Contrast Enhanced Magnetic Resonance Imaging of the Breast with pharmacokinetic (PK) modeling: Value for the Differentiation of Benign and Malignant Breast Tumors and Molecular Breast Cancer Subtypes

Rosa Elena Ochoa Albiztegui¹, Joao Vicente Machado Horvat¹, Sunitha Thakur¹, Blanca Bernard-Davila¹, Siegfried Trattnig², Thomas Helbich², Elizabeth Morris¹, and Katja Pinker-Domenig¹

¹Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ²Biomedical Imaging and Image-guided Therapy, Medical University Vienna, Vienna, Austria

To investigate ultra-high field DCE-MRI of the breast at 7T with pharmacokinetic modeling for differentiation of benign and malignant breast tumors and molecular breast cancer subtypes. 37 patients with 43 breast lesion were included and underwent a 7T DCE-MRI of the breast. Quantitative pharmacokinetic imaging biomarkers ktrans and kep aid in the differentiation of benign and malignant breast tumors. Selection of ROI- using a whole tumor and a 10mm² ROI- does not influence diagnostic accuracy. Quantitative pharmacokinetic imaging biomarkers ktrans and kep are not able to differentiate molecular breast cancer subtypes.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.